Attached.

Novelix Pharmaceuticals limited (Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956 (NOVELIX | 536565 | INE314I01036) 07th September, 2026 The Deputy Manager (Department of Corporate Affairs) BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort Mumbai- 400023 Sub: - Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”). Ref: Scrip Code: 536565 Security Id: NOVELIX Respected Sir/Madam, In compliance with Regulation 36(1)(b) of the SEBI Listing Regulations, please find attached herewith, a copy of letter which is being sent to those Members whose e-mail IDs are not registered with the Company/ Registrar and Transfer Agent/ Depository Participants, providing the web-link and path of Company’s website from where the Annual Report for the Financial Year 2025-26 and the Notice of the 32nd Annual General Meeting can be accessed. The above information is also available on the Company’s website at www.novelixpharma.com Kindly take the same on record and acknowledge receipt. Thanking You, Yours Faithfully, For Novelix Pharmaceuticals Limited Venkateshwarlu Pulluru (Whole-time director) DIN: 02076871 Novelix Pharmaceuticals limited (Formerly Known as TRIMURTHI LIMITED) H No: 3-6-237/610, Flat No: 610, 6Th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com www.novelixpharma.com Date: 07th September, 2026 Dear Shareholder, Subject: Annual Report and Notice of Annual General Meeting for the financial year 2025-26 We are pleased to inform you that the 32nd Annual General Meeting of the Company will be held on Wednesday, September 30, 2026 at 3:00 P.M. (IST) through Video Conferencing / Other Audio Visual Means. Regulation 36(1)(b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, requires listed entities to send a letter providing the web-link, including the exact path, where complete details of the Annual Report are available, to those members who have not registered their email address(es) either with the Company / Registrar and Share Transfer Agent, Venture Capital and Corporate Investments Private Limited/ Depository Participants / Depositories. In this regard, we would like to inform that Annual Report and Notice of Annual General Meeting of the Company for Financial Year 2025-26 is available and can be downloaded from below link and QR code: Website Link QR Code https://novelixpharma.com/annual-report/ We encourage you to update your email address with us so that you can receive all future communications, including the annual report, electronically. To update your email ID, please follow the process mentioned here in below: For shares held in physical mode: Shareholders, holding shares in physical mode, need to submit a request to Company’s RTA by using the SEBI prescribed ISR form, which can be downloaded from the Company’s website at www.novelixpharma.com or the website of the Company’s RTA, at https://www.vccipl.com/index.html#services. Such shareholders are requested to fill in their details, including folio number(s) and the email ID along with all requisite information as requested. Ensure signatures are as per specimen signatures registered with the Company’s RTA and submit the form to the Company’s RTA along with relevant documents ISR 2, SH 13 as per the instructions given in the form and in SEBI circular dated March 16, 2023. For shares held in dematerialized mode: Shareholders, holding shares in dematerialized mode, should contact their Depository Participant (DP) and follow the process advised by DP. This is also a reminder to update KYC details pursuant to SEBI Master Circular No. SEBI/HO/MIRSD/POD-1/P/CIR/2024/37 dated May 07, 2024, and to dematerialize physical securities. The circular issued by SEBI mandates all the listed companies to record PAN, Address with PIN code, Mobile Number, Bank Account details, Specimen Signature and choice of Nomination of security holders holding securities in physical mode. The security holders are requested to register their email id also to avail online services. This is applicable for all security holders holding securities in physical mode. The formats for choice of Nomination and Updation of KYC details via; Forms ISR-1, ISR-2, ISR-3, SH- 13, SH-14 and relevant SEBI circulars are available on our website as per below mentioned link: https://www.vccipl.com/index.html#services. Security holders holding securities in demat mode are requested to update their email address with their respective Depository Participants (DPs). If you have any queries, please feel free to contact our investor relations department at novelixpharmaceuticals@gmail.com.com or our RTA at info@vccipl.com If you wish to update or change your e-mail addresses or communication address or bank details or nomination details, please approach your respective Depository Participant in case you hold shares in electronic form OR please write to the Registrar and Transfer Agent of the Company at the below address: Name and Address: Contact Details M/s Venture Capital and Corporate Investments Email: info@vccipl.com Pvt. Limited Phone: 040-23818475/476, Fax: 040-23868024 Plot NO, 57, 5th floor, Jayabheri Enclave, Phase II, Gachibowli, Hyderabad-500032 Yours faithfully, For Novelix Pharmaceuticals limited Sd/- Venkateshwarlu Pulluru Whole Time Director DIN: 02076871